ClinicalTrials.gg

Program

Contraceptives, Oral, Combined

Also written as “Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]”, “Combined oral contraceptives (COC)” and “COC”.

Its studies are mostly in Bipolar Disorder, led by 3 companies.

Furthest: phase 1, since Jun 6, 20073 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline10 open or runningphase 1since Jun 6, 2007Jun 6, 2007none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Oct 8, 2025Oct 8, 2025none ahead
Viatris10 open or runningphase 1since Jan 29, 2020Jan 29, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2007First study: phase 1 study in Bipolar DisorderNew to GlaxoSmithKlineGlaxoSmithKline · NCT00483535 · 12 enrolled · United Kingdom
  2. Jan 29, 2020Viatris’s first study: phase 1 study in Healthy SubjectsNew to ViatrisViatris · NCT04255277 · 97 enrolled · France
  3. Oct 8, 2025Merck KGaA, Darmstadt, Germany’s first study: phase 1 study in HealthyNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT07215806 · 20 enrolled · Germany

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07215806Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyNov 25, 202220
NCT04255277Healthy Subjects · France1CompletedViatrisSep 14, 202197
NCT00483535Bipolar Disorder · United Kingdom1TerminatedGlaxoSmithKlineNov 16, 200712

How it is read

Names in the registry

  • “Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]”, 1 entry
  • “Combined oral contraceptives (COC)”, 1 entry
  • “COC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.